Every Form 4 that ENVUE MEDICAL INC NEW (FEED) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow FEED and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FEED filings page.
ENvue Medical, Inc. insider Christian Michael Glibert reported an open-market sale of 210,000 shares of Common Stock at an average price of $0.688 per share. The sale was executed in multiple transactions with prices ranging from $0.6756 to $0.722. Following this transaction, the filing shows that Glibert directly holds 0 shares of ENvue Medical common stock.
ENvue Medical, Inc. insider Christian Michael Glibert filed a Form 4 showing no change in his share count, while his beneficial ownership percentage dropped below 10 percent. He continues to hold 240,000 shares of Common Stock directly. The footnote explains that his reduced percentage resulted from dilution after ENvue issued additional shares in connection with a merger described in its Form 10-K, meaning no shares were acquired or disposed of by him.
ENvue Medical 10% owner Christian Michael Glibert bought 240,000 common shares in the open market. The purchase on January 14, 2026 was at a weighted average price of $2.67 per share, with individual trades ranging from $2.47 to $2.90.
Following this transaction, Glibert directly owns 240,000 shares of ENvue Medical common stock. A footnote states that the ownership percentage is calculated against 1,088,192 shares of common stock outstanding as of the issuer’s most recent February 2026 filings, indicating this is a meaningful stake.
Bank of America Corp, BOFA Securities and Bank of America NA jointly reported a series of open-market sales of ENvue Medical, Inc. (FEED) common stock on 02/02/2026. The trades were executed at prices generally around $3.04–$3.07 per share, each reducing the reported indirect position.
After these transactions, the reporting persons show 231,138 shares of ENvue Medical common stock beneficially owned on an indirect basis. The footnotes explain that Bank of America’s interest is indirect through its subsidiaries and include disclaimers about group status and greater-than-10% beneficial ownership.